I'm trying to find out if a ride-sharing system is being
implemented to help get people to the 9/18 rally. I believe some
financial assistance is available for cancer patients.
p.

http://www.prnewsnow.com/PR%20News%20Releases/Legal%20And%20Law/A%20Right%20To%2
0Live%20Supporters%20to%20Rally%20for%20FDA%20Reform%20and%20Call%20for%20Congre
ssional%20Action%20Provenge%20NOW

A Right To Live Supporters to Rally for FDA Reform and Call for
Congressional Action Provenge NOW

A Right To Live ( http://www.arighttolive.com ), a cancer patient
advocacy group formed to promote cancer patients' Right to Live
through access to potentially life-saving therapies, today
announces "A Right To Live Day" to be held September 18, 2007
from 10:00 am to 12:00 noon at the FDA offices in Rockville, MD.

The group will ask the FDA to immediately reconsider its flawed
decision on Provenge, among others, and approve this new therapy
for immediate use by late-stage prostate cancer patients with no
viable alternatives. This new immunotherapy has already been
endorsed by an FDA-appointed panel of experts who unanimously
(17-0) determined it to be safe for its intended use. Further,
the panel voted 13-4 in favor of the 'substantial evidence of
efficacy' of Provenge, meeting the statutory requirements for
immediate FDA approval. Never in its history had the FDA
overturned a positive panel recommendation to deny terminal
patients their right to live.

"It has become very clear over the past few years that the FDA
has instituted a decelerated approval process for cancer
therapies, in stark opposition to Congress' intent in legislating
for accelerated approval pathways," said Scott Riccio, founding
member and advocate for A Right To Live. The Wall Street Journal
lamented this problem back in 2005, noting:

"The problem here is the FDA's unethical--and let us stress,
unscientific--placebo-controlled trials, in which a subset of
study patients are knowingly denied the new treatment and in some
cases denied access to any active treatment at all. This may be
moral with an antihistamine; it's certainly not with treatments
for a terminal disease. What's more, it's entirely unnecessary.
We already know what happens to most cancer patients who don't
get treated. They die." (Wall Street Journal, March 24, 2005)

"There has never been such an incredible, irrational and
unjustifiable denial of the rights of dying patients by such a
dysfunctional agency," according to Mr. Riccio. "Approximately
27,000 men will die this year alone from late-state prostate
cancer and tens of thousands of other cancer patients will lose
their own fights against cancer this year while they wait in vain
for new therapies to make their almost ten-year march from
discovery to FDA review. We believe patients have a right to
live. We're not asking for the FDA to forego scientific review,
we're asking the Agency to catch up to the science that already
exists and use it to approve and monitor these lifesaving new
therapies while patients and their doctors get informed access to
them. We hope that if the FDA continues to abdicate its duty to
patients, Congress will make the necessary inquiries and
legislative changes to reinstate a true accelerated approval
process for them."

Patients, doctors, advocates, and other interested parties should
visit http://www.arighttolive.com for more details on getting
involved and supporting the public cry for immediate relief for
the suffering of patients being denied their right to live.

The rally will be held at 5600 Fishers Lane, Rockville, Maryland,
in front of the FDA's offices and will begin at 10:00 am.
Featured speakers will include Mr. Frank Burroughs, co-founder of
the Abigail-Alliance, Mr. Ray Matyshyn and Mr. Bruce Towers who
are both Provenge clinical trials participants, and Mr. Charles
Reinwald, President of Cancer Cure Coalition, Inc., along with
other distinguished guests.

Who is A Right To Live

A Right To Live is an all-volunteer advocacy group formed in
response to the FDA's refusal to follow the language and intent
of Congress regarding an accelerated approval process for
oncology drugs/therapies and the hundreds of thousands of
patients dying while they wait for new therapies and options to
make their way through the FDA's corrupted processes. We believe
the review process employed by the FDA is not consistent with the
law as written by Congress and as applied by current FDA
reviewers is fundamentally broken. We believe that Provenge,
Genasense, and Junovan should be approved now and would be but
for an FDA system highlighted by aggressive incompetence,
conflicts of interest, and an incorrect understanding of
Congressional intent regarding the accelerated approval process
as whole.

For media inquiries, please visit http://www.arighttolive.com or
call Scott Riccio at 312-420-3296.